Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RaFc superagonist N-803 plus BCG.

被引：0
|
作者：
Chamie, Karim
Chang, Sam S.
Kramolowsky, Eugene V.
Gonzalgo, Mark L.
Lechpammer, Stanislav
Reddy, Sandeep K.
Soon-Shiong, Patrick
机构：
[1] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Virginia Urol Ctr PC, Richmond, VA USA
[4] Univ Miami Hlth Syst, Miami, FL USA
[5] Immunitybio, El Segundo, CA USA
[6] ImmunityBio, Culver City, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
495
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FINAL CLINICAL RESULTS OF PIVOTAL TRIAL OF IL-15RAFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CIS AND PAPILLARY COHORTS
    Chang, Sam
    Chamie, Karim
    Hidalgo, Mark
    Kramolowsky, Eugene
    Sexton, Wade
    Reddy, Sandeep
    Soon-Shiong, Patrick
    JOURNAL OF UROLOGY, 2022, 207 (05): : E1047 - E1047
  • [2] PHASE 2/3 CLINICAL RESULTS OF IL-15RAFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS.
    Chamie, Karim
    Chang, Sam
    Gonzalgo, Mark
    Kramolowski, Eugene
    Reddy, Sandeep
    Soon-Shiong, Patrick
    Garner, Chad
    JOURNAL OF UROLOGY, 2021, 206 : E120 - E121
  • [3] Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients.
    Chamie, Karim
    Lee, John H.
    Rock, Amy
    Rhode, Peter R.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Phase II/III clinical results of IL-15R[alpha]Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
    Chamie, Karim
    Chang, Sam
    Gonzalgo, Mark L.
    Kramolowsky, Eugene, V
    Sexton, Wade J.
    Reddy, Sandeep K.
    Bhar, Paul
    Garner, Chad
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [5] Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
    Chamie, Karim
    Chang, Sam S.
    Gonzalgo, Mark
    Kramolowsky, Eugene V.
    Sexton, Wade J.
    Bhar, Paul
    Reddy, Sandeep K.
    Soon-Shiong, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
    Chamie, Karim
    Chang, Sam S.
    Rosser, Charles J.
    Kramolowski, Eugene
    Gonzalgo, Mark L.
    Sexton, Wade J.
    Spilman, Patricia
    Sender, Lennie
    Reddy, Sandeep
    Soon-Shiong, Patrick
    FUTURE ONCOLOGY, 2024, 20 (31) : 2307 - 2317
  • [7] Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer
    Suderman, Jonathan
    St-Laurent, Marie-Pier
    Black, Peter C.
    EUROPEAN UROLOGY, 2023, 83 (06) : 581 - 581
  • [8] A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
    Chamie, Karim
    Salmasi, Amirali
    Rosser, Charles Joel
    Rock, Amy
    Ferguson, Lydia
    Wong, Hing C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.
    Chang, Sam S.
    Chamie, Karim
    Gonzalgo, Mark L.
    Kramolowsky, Eugene V.
    Sexton, Wade J.
    Reddy, Sandeep K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists
    Moussa, Mohamad
    Chakra, Mohamad Abou
    Shore, Neal D.
    Papatsoris, Athanasios
    Farahat, Yasser
    ODonnell, Michael A.
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (01)
12345